查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1579375

抗逆轉錄病毒藥物市場：按藥物類別、給藥途徑、應用、分銷管道分類 - 全球預測 2025-2030

Anti-Retroviral Drugs Market by Drug Class: (Entry Inhibitors, Fixed-dose Combinations, Integrase Inhibitors), Route of Administration (Intravenous, Oral, Subcutaneous), Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗逆轉錄病毒藥物市值為278.2億美元，預計2024年將達290.5億美元，複合年成長率為4.59%，到2030年將達到381.2億美元。

抗逆轉錄病毒藥物市場範圍主要包括旨在預防愛滋病毒（導致愛滋病的病毒）複製的藥物。這些藥物的需求源於它們在減少病毒量、改善免疫功能以及降低與愛滋病毒感染相關的發病率和死亡率方面的重要作用。抗逆轉錄病毒藥物主要用於管理和治療愛滋病毒感染者，最終使用者包括醫院、診所和居家醫療機構。市場成長主要是由於人們對愛滋病毒和早期治療重要性的認知提高、政府舉措、對愛滋病毒/愛滋病計畫的資助以及旨在提高療效和減少副作用的藥物配方技術進步而推動的。最新的潛在機會在於開發長效注射療法和聯合治療，以提高患者的依從性和結果。此外，新興市場中愛滋病毒流行率的不斷上升帶來了巨大的成長機會。然而，該市場面臨著治療費用高、潛在副作用以及確保低收入地區藥品分配的可及性和公平性等挑戰。生技藥品的監管障礙和複雜的製造流程也對市場擴張構成了重大挑戰。為了克服這些障礙，創新應著重於降低製造成本和改善基礎設施以實現更廣泛的分銷。適合創新的研究領域包括用於靶向藥物傳輸的奈米技術、用於客製化治療的個人化醫療方法以及利用人工智慧加速藥物發現。該市場的特點是競爭激烈，少數主要企業大力投資研發和策略聯盟以保持主導地位。總體而言，策略重點是擴大服務不足地區的獲取機會並持續專注於創新治療解決方案，這將尋求利用抗逆轉錄病毒藥物領域的成長機會，這對於參與企業至關重要。

主要市場統計
基準年[2023] 278.2億美元
預測年份 [2024] 290.5億美元
預測年份 [2030] 381.2億美元
複合年成長率（%） 4.59%

市場動態：揭示快速發展的抗逆轉錄病毒藥物市場的關鍵市場洞察

供需的動態交互作用正在改變抗逆轉錄病毒藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 透過採用學名藥抗逆轉錄病毒藥物引入具有成本效益的治療方案
    • 擴大新興國家的醫療基礎設施和可近性
    • 整合數位醫療技術以改善病患管理和依從性
  • 市場限制因素
    • 接受抗逆轉錄病毒治療的恥辱和社會障礙
  • 市場機會
    • 透過整合抗逆轉錄病毒治療和個人化醫療來改善患者的治療效果
    • 加速兒科抗逆轉錄病毒的開發，以解決治療缺口
    • 加強官民合作關係，加速抗逆轉錄病毒藥物市場的研發
  • 市場問題
    • 監理合規嚴格、核准程序複雜

波特五力：駕馭抗逆轉錄病毒藥物市場的策略工具

波特的五力架構是了解抗逆轉錄病毒藥物市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解抗逆轉錄病毒病毒藥物市場的外部影響

外部宏觀環境因素在塑造抗逆轉錄病毒病毒藥物市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解抗逆轉錄病毒病毒藥物市場的競爭格局

抗逆轉錄病毒藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣抗逆轉錄病毒病毒藥物市場供應商的績效評估

FPNV定位矩陣是評估抗逆轉錄病毒藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪抗逆轉錄病毒藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，抗逆轉錄病毒藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

它也回答重要問題，幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 採用非專利抗逆轉錄病毒藥物創造了具有成本效益的治療選擇
      • 擴大新興經濟體的衛生基礎設施和服務機會
      • 整合數位醫療技術以改善病患管理和依從性
    • 抑制因素
      • 接受抗逆轉錄病毒治療的恥辱和社會障礙
    • 機會
      • 透過整合抗逆轉錄病毒治療和個人化醫療來改善患者的治療效果
      • 加速兒科抗逆轉錄病毒的開發以填補治療空白
      • 抗逆轉錄病毒藥物市場加強公私合營並促進研究和開發
    • 任務
      • 監理合規嚴格、核准程序複雜
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章抗逆轉錄病毒藥物市場：依藥物類別

  • 介紹
  • 進入抑制劑
  • 固定劑量組合
  • 整合酶抑制劑
  • 非核苷類逆轉錄酶抑制劑
  • 核苷逆轉錄酶抑制劑
  • 蛋白酶抑制劑

第7章抗逆轉錄病毒藥物市場：依途徑

  • 介紹
  • 靜脈
  • 口服
  • 皮下的

第8章抗逆轉錄病毒藥物市場：依應用分類

  • 介紹
  • 愛滋病毒治療
  • 暴露後預防
  • 暴露前預防

第9章抗逆轉錄病毒藥物市場：依分銷管道分類

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章美洲抗逆轉錄病毒藥物市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區抗逆轉錄病毒藥物市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲抗逆轉錄病毒藥物市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准Dovato 用於治療 12 歲及以上 HIV 感染者，標誌著治療和依從性方面取得重大進展
    • Zydus Lifesciences 的非專利地蘆那韋片獲得美國FDA核准
  • 戰略分析和建議
    • Cipla Limited

公司名單

  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • APOTEX INC.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Drugs Limited
  • Janssen Pharmaceuticals, Inc. by Johnson & Johnson
  • Jubilant Life Sciences Limited
  • Lupin Limited
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Mylan Laboratories by Viatris Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • ViiV Healthcare
Product Code: MRR-1A1A064C02F2

The Anti-Retroviral Drugs Market was valued at USD 27.82 billion in 2023, expected to reach USD 29.05 billion in 2024, and is projected to grow at a CAGR of 4.59%, to USD 38.12 billion by 2030.

The scope of the anti-retroviral drugs market primarily encompasses medications designed to prevent the replication of HIV, the virus that causes AIDS. The necessity of these drugs stems from their critical role in reducing viral load, improving immune function, and decreasing morbidity and mortality associated with HIV infection. Applications of anti-retroviral drugs are primarily in the management and treatment of HIV-infected individuals, with end-users including hospitals, clinics, and home care settings. Market growth is heavily influenced by increasing awareness about HIV and the importance of early treatment, government initiatives, and funding for HIV/AIDS programs, coupled with technological advancements in drug formulations for improved efficacy and reduced side effects. The latest potential opportunities lie in developing long-acting injectable treatments and combination therapies that improve patient adherence and outcomes. Additionally, the growing prevalence of HIV in emerging markets presents substantial growth opportunities. However, the market faces limitations such as high costs of treatment, potential side effects, and challenges in ensuring accessibility and equity in drug distribution in low-income regions. Regulatory hurdles and the complex manufacturing process of these biologics also pose significant challenges to market expansion. To overcome these barriers, innovation should focus on reducing production costs and improving infrastructure for broader distribution. Research areas ripe for innovation include nanotechnology for targeted drug delivery, personalized medicine approaches for tailored treatments, and leveraging AI to accelerate drug discovery. The market is characterized by intense competition, with a few dominant players investing heavily in R&D and strategic collaborations to maintain their leadership position. Overall, a strategic emphasis on expanding access in underserved regions, coupled with a sustained focus on innovative therapeutic solutions, will be essential for market participants seeking to leverage growth opportunities in the anti-retroviral drugs sector.

KEY MARKET STATISTICS
Base Year [2023] USD 27.82 billion
Estimated Year [2024] USD 29.05 billion
Forecast Year [2030] USD 38.12 billion
CAGR (%) 4.59%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Retroviral Drugs Market

The Anti-Retroviral Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Introduction of generic antiretroviral drugs leading to cost-effective treatment options
    • Expanding healthcare infrastructure and accessibility in emerging economies
    • Integration of digital health technologies for better patient management and adherence
  • Market Restraints
    • Stigma and social barriers limiting the uptake of anti-retroviral therapies
  • Market Opportunities
    • Integration of anti-retroviral therapies with personalized medicine for improved patient outcomes
    • Accelerating development of pediatric anti-retroviral formulations to address treatment gaps
    • Enhancing public-private partnerships to boost research and development in the anti-retroviral drugs market
  • Market Challenges
    • Stringent regulatory compliance and complex approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Retroviral Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Retroviral Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Retroviral Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Retroviral Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Retroviral Drugs Market

A detailed market share analysis in the Anti-Retroviral Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Retroviral Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Retroviral Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Retroviral Drugs Market

A strategic analysis of the Anti-Retroviral Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Retroviral Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkem Laboratories Ltd., APOTEX INC., Aurobindo Pharma Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Hetero Drugs Limited, Janssen Pharmaceuticals, Inc. by Johnson & Johnson, Jubilant Life Sciences Limited, Lupin Limited, MacroGenics, Inc., Merck & Co., Inc., Mylan Laboratories by Viatris Inc., Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and ViiV Healthcare.

Market Segmentation & Coverage

This research report categorizes the Anti-Retroviral Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class:, market is studied across Entry Inhibitors, Fixed-dose Combinations, Integrase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Subcutaneous.
  • Based on Application, market is studied across HIV Treatment, Post-exposure Prophylaxis, and Pre-exposure Prophylaxis.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Introduction of generic antiretroviral drugs leading to cost-effective treatment options
      • 5.1.1.2. Expanding healthcare infrastructure and accessibility in emerging economies
      • 5.1.1.3. Integration of digital health technologies for better patient management and adherence
    • 5.1.2. Restraints
      • 5.1.2.1. Stigma and social barriers limiting the uptake of anti-retroviral therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of anti-retroviral therapies with personalized medicine for improved patient outcomes
      • 5.1.3.2. Accelerating development of pediatric anti-retroviral formulations to address treatment gaps
      • 5.1.3.3. Enhancing public-private partnerships to boost research and development in the anti-retroviral drugs market
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory compliance and complex approval procedures
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Retroviral Drugs Market, by Drug Class:

  • 6.1. Introduction
  • 6.2. Entry Inhibitors
  • 6.3. Fixed-dose Combinations
  • 6.4. Integrase Inhibitors
  • 6.5. Non-Nucleoside Reverse Transcriptase Inhibitors
  • 6.6. Nucleoside Reverse Transcriptase Inhibitors
  • 6.7. Protease Inhibitors

7. Anti-Retroviral Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Subcutaneous

8. Anti-Retroviral Drugs Market, by Application

  • 8.1. Introduction
  • 8.2. HIV Treatment
  • 8.3. Post-exposure Prophylaxis
  • 8.4. Pre-exposure Prophylaxis

9. Anti-Retroviral Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Anti-Retroviral Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anti-Retroviral Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anti-Retroviral Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA approval of Dovato for adolescents 12 and older living with HIV marks a significant breakthrough in treatment and adherence
    • 13.3.2. Zydus Lifesciences secures USFDA nod for generic Darunavir Tablets
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Cipla Limited

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alkem Laboratories Ltd.
  • 3. APOTEX INC.
  • 4. Aurobindo Pharma Limited
  • 5. Boehringer Ingelheim GmbH
  • 6. Bristol-Myers Squibb Company
  • 7. Cipla Limited
  • 8. Dr. Reddy's Laboratories Ltd.
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline plc
  • 11. Hetero Drugs Limited
  • 12. Janssen Pharmaceuticals, Inc. by Johnson & Johnson
  • 13. Jubilant Life Sciences Limited
  • 14. Lupin Limited
  • 15. MacroGenics, Inc.
  • 16. Merck & Co., Inc.
  • 17. Mylan Laboratories by Viatris Inc.
  • 18. Mylan N.V.
  • 19. Novartis AG
  • 20. Pfizer Inc.
  • 21. Roche Holding AG
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Torrent Pharmaceuticals Ltd.
  • 25. ViiV Healthcare

LIST OF FIGURES

  • FIGURE 1. ANTI-RETROVIRAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-RETROVIRAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTI-RETROVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTI-RETROVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-RETROVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-RETROVIRAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIXED-DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HIV TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY POST-EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRE-EXPOSURE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DRUG CLASS:, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. ANTI-RETROVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. ANTI-RETROVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023